Buprenorphine Patch
Product Images NDC 42858-586

Product Visual Gallery

This gallery contains 25 technical images submitted to the FDA as part of the official labeling for Buprenorphine (NDC 42858-586). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rhodes Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Buprenorphine 01)

Chemical structure of Buprenorphine, showing its molecular configuration with multiple rings, hydroxyl, methyl, and methoxy functional groups, and nitrogen atoms as part of the structure.*

FDA Label Image

Figure 1 (Buprenorphine 02)

Illustration diagram showing the five layers of a Buprenorphine transdermal patch, including the backing layer, overlapping adhesive film, separating layer, drug/polymer adhesive matrix, and peel-off release liner.*

FDA Label Image

Figure 2 (Buprenorphine 03)

A line chart depicting the concentration of buprenorphine (pg/mL) over 26 days following application of a 10 mcg/hour buprenorphine transdermal system every 7 days for three cycles (N=36). The x-axis represents time in days, while the y-axis shows concentration levels, with a marked point indicating buprenorphine transdermal system removal near day 21.*

FDA Label Image

Figure 3 (Buprenorphine 04)

A line graph comparing the percentage of patients improved versus the percent reduction or improvement in pain. Two lines represent Placebo (open circles) and Buprenorphine Transdermal System 10/20 (filled squares), showing patient response rates across different pain reduction thresholds.*

FDA Label Image

Figure 4 (Buprenorphine 05)

A line graph comparing the percentage of patients with pain improvement between Buprenorphine Transdermal System 5 and Buprenorphine Transdermal System 20. The x-axis shows percent reduction/improvement in pain, and the y-axis shows the percentage of patients improved, illustrating higher patient improvement rates with the 20 dose system.*

FDA Label Image

Figure A (Buprenorphine 06)

An instructional illustration showing potential placement sites for Buprenorphine transdermal patches on the human body. It depicts patches applied on the upper arm, upper chest near the shoulder, upper back near the shoulder blade, and the side of the torso under the arm.*

FDA Label Image

Figure B (Buprenorphine 07)

An illustration showing the placement of two transdermal Buprenorphine patches on the upper back and shoulder area. The diagram demonstrates correct patch application sites for the Buprenorphine transdermal system.*

FDA Label Image

Figure C (Buprenorphine 08)

An instructional line drawing showing a person holding scissors near the center of the upper chest, illustrating how to cut or prepare the skin area, likely for application of a transdermal patch such as Buprenorphine.*

FDA Label Image

Figure D (Buprenorphine 09)

An instructional line drawing showing hands using scissors to cut open a pouch or package, likely demonstrating how to properly open a sealed package for a transdermal patch such as Buprenorphine patch.*

FDA Label Image

Figure E (Buprenorphine 10)

Illustration showing a Buprenorphine transdermal patch with labels identifying the patch, foil backing, and foil handle. The diagram highlights the components of the patch packaging for removal and application.*

FDA Label Image

Figure F (Buprenorphine 11)

Instructional illustration showing a person peeling a Buprenorphine transdermal patch from its protective backing. The hands in the image demonstrate how to carefully remove the patch for application.*

FDA Label Image

Figure G (Buprenorphine 12)

An instructional illustration showing a person applying a transdermal patch to the upper chest area. The image depicts the correct placement of a patch on bare skin of the chest.*

FDA Label Image

Figure H (Buprenorphine 13)

Illustration showing a person applying a Buprenorphine transdermal patch to the upper chest or shoulder area. The image depicts the hands placing the patch on the skin, demonstrating the transdermal route of administration for the patch dosage form by Rhodes Pharmaceuticals LLC.*

FDA Label Image

Figure I (Buprenorphine 14)

An instructional illustration showing a person applying a transdermal patch to the upper chest area near the shoulder. The image demonstrates the correct placement of Buprenorphine patch, a transdermal medication used for prescription drug treatment.*

FDA Label Image

Figure J (Buprenorphine 15)

An instructional illustration showing a pair of hands holding an unfolded package or card with the heading 'STEP 1'. The illustration appears to be demonstrating the first step in the application or use of a product, likely related to Buprenorphine transdermal patches based on the product data provided.*

FDA Label Image

Figure K (Buprenorphine 16)

Instructional illustration showing hands peeling back the Step 2 layer of a Buprenorphine transdermal patch package, demonstrating how to open the patch for application.*

FDA Label Image

Figure L (Buprenorphine 17)

An instructional line drawing showing hands holding an open pamphlet or instruction sheet. The visible text reads 'STEP 3' followed by instructions related to folding over sealed patch packaging and peeling it away. This likely demonstrates how to properly open or apply a transdermal patch for Buprenorphine.*

FDA Label Image

Figure M (Buprenorphine 18)

An instructional line drawing showing two hands peeling apart layers of packaging, likely demonstrating how to open or prepare a transdermal patch. There are no visible text or labels in the image.*

FDA Label Image

Figure N (Buprenorphine 19)

Illustration showing a hand discarding a square adhesive patch into a trash can with an open lid. The image visually suggests proper disposal of the patch, likely related to the Buprenorphine transdermal patch.*

FDA Label Image

Figure O (Buprenorphine 20)

An instructional illustration showing a hand discarding a used Buprenorphine transdermal patch into a toilet. The image highlights proper disposal technique for the medication patch, depicting a toilet with the seat cover raised and the patch being dropped inside.*

FDA Label Image

Principal Display Panel (5 mcg/hour Patch Pouch Carton)

Packaging label for Buprenorphine Transdermal System 5 mcg/hour patch by Rhodes Pharmaceuticals LLC. The label displays the product name, strength, dosage form as transdermal system, and includes warnings and dispensing instructions. The label indicates the package contains 4 transdermal systems and provides space for a pharmacy label. NDC 42858-750-40 is visible.*

FDA Label Image

Principal Display Panel (7.5 mcg/hour Patch Pouch Carton)

Packaging label for Buprenorphine Transdermal System 7.5 mcg/hour patch by Rhodes Pharmaceuticals LLC. The label indicates a package containing 4 transdermal systems (disposable units) for systemic delivery of 7.5 mcg per hour of buprenorphine. It includes warnings and instructions, with emphasis on use only for experienced opioid patients. The label features NDC 42858-353-40 and space for a pharmacy label.*

FDA Label Image

Principal Display Panel (10 mcg/hour Patch Pouch Carton)

Packaging label for Buprenorphine Transdermal System 10 mcg/hour patch by Rhodes Pharmaceuticals LLC. The label indicates this is a transdermal patch delivering 10 mcg of buprenorphine per hour. The box contains 4 transdermal systems, with instructions for use and warnings including dispensing a medication guide. The label shows the NDC 42858-493-40.*

FDA Label Image

Principal Display Panel (15 mcg/hour Patch Pouch Carton)

The image shows the packaging label for Buprenorphine Transdermal System 15 mcg/hour, a transdermal patch. The label states it contains 4 transdermal systems in one package, intended for systemic delivery of 15 mcg per hour of buprenorphine for seven days. The label includes warnings against use for certain types of pain and emphasizes dispensing with a medication guide. The labeler is Rhodes Pharmaceuticals LLC, and the NDC is 42858-586-40. There are designated areas labeled 'No Varnish Area' and a section for affixing a pharmacy label.*

FDA Label Image

Principal Display Panel (20 mcg/hour Patch Pouch Carton)

Packaging label for Buprenorphine Transdermal System 20 mcg/hour patch by Rhodes Pharmaceuticals LLC. The label indicates the product is a transdermal system delivering 20 mcg of buprenorphine per hour. The package contains four transdermal systems. The label includes warnings about respiratory risks, directions that it is for opioid-experienced patients only, and a space designated for a pharmacy label. The NDC number 42858-839-40 appears on the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.